Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cardiac sodium channel protein type 5 subunit alpha (NaV1.5), encoded by the SCN5A gene, forms the primary ion channel responsible for the rapid upstroke (phase 0) of the cardiac action potential, enabling rapid electrical conduction across the heart muscle[3][5]. In addition to the large, transient early sodium current, a small fraction of these channels either fail to inactivate or reopen during the plateau phase, generating a sustained or "late" sodium current (I_Na,late)[1][2][3]. This late current, although much smaller in magnitude, significantly influences action potential duration and intracellular sodium and calcium levels, with overactivity implicated in various cardiac pathologies such as arrhythmias and heart failure[2][3]. Drugs targeting this late current are used as antiarrhythmic agents and are under investigation for other cardiac indications[2][3].
Inhibition of the late sodium current to reduce prolonged action potential duration and decrease intracellular sodium and calcium overload Blockade of voltage-gated sodium channels to suppress abnormal electrical activity
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cardiac sodium channel protein type 5 subunit alpha (NaV1.5) (NaV1.5).